

Title (en)
USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR USE IN A METHOD FOR THE TREATMENT OR PREVENTION OF ANDROGEN DEFICIENCY

Title (de)
VERWENDUNG EINES SELEKTIVEN ÖSTROGENREZEPTORMODULATORS ZUR HERSTELLUNG EINES PHARMAZEUTISCHEN PRÄPARATES ZUR VERWENDUNG IN EINEM VERFAHREN FÜR DIE BEHANDLUNG ODER VORBEUGUNG VON ANDROGENMANGEL

Title (fr)
UTILISATION D'UN MODULATEUR SELECTIF DU RECEPTEURS DES OESTROGENES DANS LA FABRICATION D'UNE PREPARATION PHARMACEUTIQUE UTILISEE DANS UNE METHODE DE TRAITEMENT OU DE PREVENTION DES INSUFFISANCES ENDROGENIQUES

Publication
EP 1786408 A4 20100728 (EN)

Application
EP 05771627 A 20050720

Priority
• FI 2005000333 W 20050720
• US 60690704 P 20040903
• FI 20041216 A 20040921

Abstract (en)
[origin: WO2006024689A1] This invention relates to a use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency or diseases and disorders caused by androgen deficiency in a male individual.

IPC 8 full level
A61K 31/085 (2006.01); **A61K 31/10** (2006.01); **A61K 31/135** (2006.01); **A61K 31/395** (2006.01); **A61K 31/4164** (2006.01); **A61P 5/26** (2006.01); **A61P 5/32** (2006.01)

CPC (source: EP KR US)
A61K 31/00 (2013.01 - EP); **A61K 31/085** (2013.01 - EP KR); **A61K 31/10** (2013.01 - EP); **A61K 31/135** (2013.01 - EP KR); **A61K 31/395** (2013.01 - EP US); **A61K 31/4164** (2013.01 - EP KR); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/14** (2017.12 - EP); **A61P 5/26** (2017.12 - EP); **A61P 5/30** (2017.12 - EP); **A61P 5/32** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 15/10** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 35/00** (2017.12 - EP)

Citation (search report)
• [XY] WO 0136360 A1 20010525 - HORMOS MEDICAL OY LTD [FI], et al
• [XY] DUSCHEK ERIK J J ET AL: "Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04-01), pages 539 - 546, XP002586475, ISSN: 0804-4643
• [XY] STEINER MITCHELL S ET AL: "Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia.", CLINICAL PROSTATE CANCER JUN 2003 LNKD- PUBMED:15046680, vol. 2, no. 1, June 2003 (2003-06-01), pages 24 - 31, XP009134590, ISSN: 1540-0352
• See references of WO 2006024689A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2006024689 A1 20060309; AU 2005279178 A1 20060309; BR PI0514701 A 20080624; CA 2578852 A1 20060309; EP 1786408 A1 20070523; EP 1786408 A4 20100728; JP 2008511615 A 20080417; KR 20070059110 A 20070611; MX 2007002606 A 20070515; NO 20071160 L 20070525; RU 2007112114 A 20081010

DOCDB simple family (application)
FI 2005000333 W 20050720; AU 2005279178 A 20050720; BR PI0514701 A 20050720; CA 2578852 A 20050720; EP 05771627 A 20050720; JP 2007529372 A 20050720; KR 20077006922 A 20070327; MX 2007002606 A 20050720; NO 20071160 A 20070301; RU 2007112114 A 20050720